Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 8
Submit an article Journal homepage
190
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

How much to worry about the FDA warning in the use of citalopram?

Sheng-Min Wang Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea
&
Chi-Un Pae Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea. [email protected]; Department of Psychiatry and Behavioral Medicines, Duke University Medical Center, Durham, NC, USA; Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea. [email protected]; Department of Psychiatry and Behavioral Medicines, Duke University Medical Center, Durham, NC, USA
Pages 883-886 | Published online: 09 Jan 2014

References

  • Marks DM, Park MH, Ham BJ et al. Paroxetine: safety and tolerability issues. Expert Opin. Drug Saf. 7(6), 783–794 (2008).
  • Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373(9665), 746–758 (2009).
  • U.S. Food and Drug Administration. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). (Accessed February 2013).
  • U.S. Food and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. (Accessed February 2013).
  • Pae CU. Sertindole: dilemmas for its use in clinical practice. Expert Opin. Drug Saf. 12(3), 321–326 (2013).
  • Zivin K, Pfeiffer PN, Bohnert AS et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am. J. Psychiatry 170(6), 642–650 (2013).
  • McKean AJ, Sola CL, Galardy C, Kung S, Lineberry TW. Reconciling the risk of QT interval prolongation in antidepressants. Pharmacoepidemiol. Drug Saf. 21(3), 329–330; author reply 331–332 (2012).
  • Desai VC, Heaton PC, Kelton CM. Impact of the Food and Drug Administration’s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings. Alzheimers. Dement. 8(5), 453–457 (2012).
  • Temple R, Laughren T, Stockbridge N. Removal from labeling of 60-mg citalopram dose. Pharmacoepidemiol. Drug Saf. 21(7), 784–786 (2012).
  • Roden DM. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350(10), 1013–1022 (2004).
  • Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 39(4), 128–134 (2006).
  • Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J. Biol. Psychiatry 11(2 Pt 2), 300–307 (2010).
  • American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder (3rd edition). (2011).
  • Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol. Drug Saf. 20(9), 903–913 (2011).
  • Martinez C, Assimes TL, Mines D, Dell’aniello S, Suissa S. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ 340, c249 (2010).
  • Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J. Clin. Psychopharmacol. 19(5), 407–415 (1999).
  • Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J. Psychopharmacol. 22(4), 343–396 (2008).
  • Menon-Andersen D, Yu B, Madabushi R et al. Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label. Clin. Pharmacol. Ther. 90(3), 471–474 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.